Dose-response of vasopressin in a rat model of asphyxial cardiac arrest

Am J Emerg Med. 2009 Oct;27(8):935-41. doi: 10.1016/j.ajem.2008.07.031.

Abstract

The advantage of vasopressin over epinephrine in the treatment of cardiac arrest (CA) is still being debated, and it is not clear whether a high dose of vasopressin is beneficial or detrimental during or after cardiopulmonary resuscitation (CPR) in a rat model of CA. In this study, asphyxial CA was induced in 40 male Sprague-Dawley rats. After 10 minutes of asphyxia, CPR was initiated; and the effects of different doses of vasopressin (low dose, 0.4 U/kg; medium dose, 0.8 U/kg; and high dose, 2.4 U/kg; intravenous; n = 10 in each group) and a saline control (isotonic sodium chloride solution, 1 mL, intravenous) were compared. Outcome measures included the rate of restoration of spontaneous circulation (ROSC) and changes of hemodynamic and respiratory variables after ROSC. The rates of ROSC were 1 of 10 in the saline group and 8 of 10 in each of the 3 vasopressin groups. There were no differences in mean aortic pressure or changes of respiratory function after CPR among the vasopressin groups. However, the heart rate was lower in the high-dose vasopressin group than in the low- and medium-dose groups. These findings indicate that different doses of vasopressin result in a similar outcome of CPR, with no additional benefits afforded by a high dose of vasopressin during or after CPR, in a rat model of asphyxial CA. The mechanism and physiologic significance of the relative bradycardia that occurred in the high-dose vasopressin group are currently unknown and require further investigation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Asphyxia / complications*
  • Cardiopulmonary Resuscitation
  • Disease Models, Animal
  • Dose-Response Relationship, Drug
  • Heart Arrest / drug therapy*
  • Heart Arrest / etiology
  • Male
  • Rats
  • Rats, Sprague-Dawley
  • Vasoconstrictor Agents / administration & dosage
  • Vasoconstrictor Agents / pharmacology*
  • Vasopressins / administration & dosage
  • Vasopressins / pharmacology*

Substances

  • Vasoconstrictor Agents
  • Vasopressins